Clinical trials: Natural Killer Cell Malignancies
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Cortisol Excess, Stress, Psychological
Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of Bogotá
Recent studies on health personnel in Colombia have evidenced the considerable increase in the levels of stress and anxiety, among other psychological disorders, as a product of the COVID-19 pandemic that is being experienced…
- Conditions
- Cortisol Excess, Stress, Psychological, Anxiety, Epigenetic Disorder
- Trial name
- NCT05315388
- Testing
- Immersion therapy in nature - Vitamin N
- Where
- Colombia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Jeadran N. Malagón-Rojas
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoblastic Leukemia, Acute
Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
- Trial name
- NCT00995137
- Testing
- NK Cell Infusion
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroblastoma Recurrent
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells
Neuroblastoma is a neoplasm of the sympathetic nervous system which affects mostly children younger than 5 years of age. It is a heterogeneous disease, with nearly 50% of patients presenting with a high-risk phenotype.
- Trial name
- NKEXPGD2 (NCT03242603)
- Testing
- Anti-GD2 in combination with NK cells
- Where
- Singapore
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2…
- Trial name
- NCT06026657
- Testing
- Biospecimen Collection, Computed Tomography, Gemcitabine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Margaret Gatti-Mays
Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic…
- Conditions
- Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- DUET-BTC (NCT07641036)
- Testing
- EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Lymphoma, Extranodal NK-T-Cell
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F- FDG PET/CT and predict disease progression during chemotherapy or survival in…
- Trial name
- NCT03051542
- Testing
- 18F-FDG PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy.
- Conditions
- Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT07225439
- Testing
- Allogeneic NK cells, Rituximab, Tafasitamab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Paolo Caimi, MD
Non-small Cell Lung Cancer
A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment
This clinical trial is a Single-Center, Open, Phase I/IIa Clinical Trial conducted to evaluate the safety and anti-tumor activity of SNK01 and GC +/- Cetuximab administered in combination to Locally advanced or Metastatic…
- Trial name
- SNK_ASTER (NCT04872634)
- Testing
- SNK01 (Super Natural Killer Cells 01), GC, Cetuximab
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- NKMAX Co., Ltd.
Hepatocellular Carcinoma
Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer
Study hypothesis: The recurrence rate of HCC patients after radical resection is about 60-70%. This study is based on the hypothesis that CIK treatment could decrease the recurrence rate by 15% to 20%.
- Trial name
- HCC-CIK (NCT00769106)
- Testing
- cytokine-induced killer cell (CIK) treatment
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities
Pancreatic cancer is the 5th leading cause of cancer death and the worst prognostic cancer in the world. This is due to high recurrent rate after surgical resection and poor response to chemotherapy and radiotherapy.
- Trial name
- NCT02887599
- Testing
- Blood collection
- Where
- South Korea
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
CIML NK Cell in Head & Neck Cancer
This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer.
- Trial name
- NCT04290546
- Testing
- Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer, Squamous Cell Carcinoma
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
This randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell…
- Trial name
- CIK (NCT01631357)
- Testing
- CIK cell, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neuroblastoma, High-Risk
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for…
- Trial name
- NCT02650648
- Testing
- cyclophosphamide, NK cells, hu3F8
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma
Nasal/nasal type NK-T-cell lymphoma is a rare and severe type of non-Hodgkin's lymphoma (NHL) more frequent in Asia than in western countries. When localised, radiotherapy seems to be the best treatment.
- Trial name
- NCT00283985
- Testing
- Kidrolase, Methotrexate, Dexamethasone
- Where
- 25 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Acute Myeloid Leukemia or Myelodysplasic Syndrome
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
This project is a framework for developing new therapeutic strategies for acute myeloid leukemia(AML)based immunotherapy. the role of NK cells was demonstrated in AML and especially GVL effect (graft versus leukemia) during…
- Trial name
- NCT02525250
- Testing
- Realization of 3 Blood samples during study during treatment with lenalidomide
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Institut Paoli-Calmettes
Primary Sjogren's Syndrome, Lymphoma
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
This study is a phase I-II clinical trial of CAR-NK cell therapy for high-risk lymphoma patients with primary Sjogren's syndrome (pSS).
- Trial name
- CAR-NK (NCT06967038)
- Testing
- CAR-NK cell
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Bangdong Gong
Extranodal NK/T-cell Lymphoma, Nasal Type
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%.
- Trial name
- NCT02631239
- Testing
- Methotrexate, Etoposide, Dexamethasone
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Ruijin Hospital